JNJ-42226314

SKU: orb1709362

Description

JNJ-42226314 is a potent, selective, and non-covalent inhibitor of monoacylglycerol lipase (MAGL). Its efficacy in neuropathic and inflammatory pain models is mediated by elevating endogenous 2-arachidonoylglycerol (2-AG) levels, supporting its use in cannabinoid-related in vivo pain research.

Research Area

Metabolism Research

Key Properties

• CAS Number: 1252765-13-1
• MW: 489.56
• Purity: 99.74% (May vary between batches)
• Formula: C₂₆H₂₄FN₅O₂S
• SMILES: Fc1ccc(cc1)-n1ccc2cc(ccc12)C(=O)N1CC(C1)N1CCN(CC1)C(=O)c1nccs1
• Target: Lipase,MAGL
• Solubility: 10% DMSO+40% PEG300+5% Tween 80+45% Saline:5 mg/mL (10.21 mM);DMSO:100 mg/mL (204.27 mM)

Bioactivity

• In Vivo:
  In male C57Bl/6 mice weighing 20-30g and male Sprague-Dawley rats weighing 300-400g, treatment with JNJ-42226314 (3 mg/kg and 30 mg/kg; i.p.; 120 min) dose-dependently elevated hippocampal 2-AG levels in vivo.
  Read more...
• In Vitro:
  After treatment with PF-3845 ( 1 or 10 μM ), JZL-184 ( 1 or 10 μM ), JNJ-42226314 ( 1 or 10 μM ) or carrier ( DMSO ), JNJ-42226314 was selectively analyzed by competitive ABPP. The results showed that JNJ-42226314 had high selectivity for MAGL .
  Read more...

Storage & Handling

• Storage: -20°C
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only

Alternative Names

JNJ 42226314, JNJ42226314, JNJ-42226314, MAGL

Compound Identifiers

PubChem CID

59625954